ISRCTN74332440已完成未知
A double-blind, randomized, placebo-controlled crossover trial of a Lactobacillus salivarius WB21-containing tablet for treatment of oral malodor
Fukuoka Dental College (Japan)0 个研究点目标入组 26 人开始时间: 2013年1月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
2014 results in https://pubmed.ncbi.nlm.nih.gov/24556493/ (added 17/12/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. 26 eligible patients (22 females and four males; mean age, 43.5 ± 11.5 years; age range, 22?67 years)
- •2. Oral malodor above a questionable level (OLT score = 1.5)
- •3. Not currently visiting a dentist for treatment
- •4. No acute symptoms requiring immediate oral cavity treatment
- •5. No use of probiotic supplements
- •6. No antibiotic use within the last month
- •7. No daily smoking habit
- •8. No systemic illness
- •9. No adverse reactions to lactose or fermented milk products
排除标准
- •Does not meet inclusion criteria
- •56 were excluded: 48 did not meet the inclusion criteria, three refused to participate, and five had personality traits that were considered difficult for adherence to the protocol.
研究者
相似试验
已完成
不适用
The influence of ivabradine in a healthy volunteer pain modelISRCTN97420179Cambridge University Hospitals NHS Foundation trust & University of Cambridge (UK)55
已完成
不适用
SUBpectoral Local anaesthetic Infusion following MastEctomy - version 1 (SUBLIME)Breast CancerCancerISRCTN46621916Royal Cornwall Hospitals NHS Trust (UK)160
已完成
2 期
Effect of concomitant treatment with an androgen on sexual functioning in women using an oral contraceptioISRCTN03247616Pantarhei Bioscience BV (Netherlands)81
已完成
不适用
Clinical trial for proving the efficacy of heat-inactivated Bifidobacterium bifidum SYN-HI-001 in the treatment of irritable bowel syndromeIrritable bowel syndrome (IBS)Digestive SystemISRCTN14066467Synformulas GmbH507
已完成
不适用
Phase III randomised, double-blind, placebo-controlled trial of Gefitinib (Iressa®) versus placebo in Oesophageal Cancer progressing after chemotherapyCancerOesophageal cancerISRCTN29580179niversity of Oxford (UK)450